Margins on cancer drugs have risen sharply, from 30% in 2019 to 700% today
A Times of India report says profit margins on cancer medicines have climbed from about 30% in 2019 to as high as 700% at present. The rise is attributed to pricing practices within the drug supply chain rather than to production costs alone. The article notes that the widening gap has raised concerns about the affordability of treatment for patients. Industry and policy observers have called for closer scrutiny of how these medicines are priced and sold.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.
Discussion (0)
Log in to join the discussion and vote.
Log in